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Genome-wide rare copy number variation
screening in ulcerative colitis identifies
potential susceptibility loci
Hamid Reza Saadati1, Michael Wittig1, Ingo Helbig2, Robert Häsler1, Carl A. Anderson3, Christopher G. Mathew4,
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Abstract
Background: Ulcerative colitis (UC), a complex polygenic disorder, is one of the main subphenotypes of
inflammatory bowel disease. A comprehensive dissection of the genetic etiology of UC needs to assess the
contribution of rare genetic variants including copy number variations (CNVs) to disease risk. In this study, we
performed a multi-step genome-wide case-control analysis to interrogate the presence of disease-relevant rare
copy number variants.
Methods: One thousand one hundred twenty-one German UC patients and 1770 healthy controls were initially
screened for rare deletions and duplications employing SNP-array data. Quantitative PCR and high density custom
array-CGH were used for validation of identified CNVs and fine mapping. Two main follow-up panels consisted of
an independent cohort of 451 cases and 1274 controls, in which CNVs were assayed through quantitative PCR, and
a British cohort of 2396 cases versus 4886 controls with CNV genotypes based on array data. Additional sample sets
were assessed for targeted and in silico replication.
Results: Twenty-four rare copy number variants (14 deletions and 10 duplications), overrepresented in UC patients
were identified in the initial screening panel. Follow-up of these CNV regions in four independent case-control series as
well as an additional public in silico control group (totaling 4439 UC patients and 15,961 healthy controls) revealed
three copy number variants enriched in UC patients; a 15.8 kb deletion upstream of ABCC4 and CLDN10 at13q32.1
(0.43 % cases, 0.11 % controls), a 119 kb duplication at 7p22.1, overlapping RNF216, ZNF815, OCM and CCZ1 (0.13 %
cases, 0.01 % controls) and a 134 kb large duplication upstream of the KCNK9 gene at 8q24.3 (0.22 % carriers among
cases, 0.03 % carriers among controls). The trend of association with UC was present after the P-values were corrected
for combining data from different subpopulations. Break-point mapping of the deleted region suggested non-allelic
homologous recombination as the mechanism underlying its formation.
Conclusion: Our study presents a pragmatic approach for effective rare CNV screening of SNP-array data sets and
implicates the potential contribution of rare structural variants in the pathogenesis of UC.
Keywords: Ulcerative colitis, Copy number variation, Rare variants, SNP array, Case-control association
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Background
Ulcerative colitis (UC) represents one major subpheno-
type (OMIM 191390) of human inflammatory bowel dis-
ease (IBD, OMIM 266600) and is characterized by
chronic inflammation of the intestinal mucosa, exhibit-
ing a continuous pattern in the affected tissue. The dis-
ease is more frequent in the northern hemisphere with
the prevalence rates ranging from 21 to 246 per 100,000
in North America and Europe [1]. Population-based ob-
servations of an 8- to 10-fold greater disease risk among
first-degree relatives of UC patients have demonstrated
that inherited risk factors contributes to the pathogen-
esis of UC [2]. However the disease is mainly triggered
in genetically susceptible individuals by environmental
risk factors [3].
The genetic contribution to UC has been mainly inter-
rogated through genome-wide association studies
(GWAS) of mostly common single nucleotide polymor-
phisms (SNP) represented on oligo-nucleotide microar-
rays (SNP-array) in the last decade. Subsequent meta
analyses of these SNP-GWAS data have substantially in-
creased the number of UC susceptibility loci (n > 130),
nevertheless the identified risk alleles are mostly of low
to modest effects (odds ratio <1.5) and explain less than
15 % of the overall variance in UC risk [4, 5]. It has been
assumed that genomic structural variations including
CNVs are among the factors that potentially account for
the bulky missing heritability of complex disease pheno-
types [6]. CNVs comprise insertions, duplications and
deletions of genomic sequences, ranging in size from less
than 100 base pairs (bp) to greater than 1 Mbp and con-
tribute to higher (>100 fold) DNA sequence variation
between individual genomes than do SNPs [7, 8]. Com-
mon CNVs, with population frequency of > 1 %, often
exist in multi-copy number states ranging from 0 to 30
copies per diploid genome [9]. Disease relevance of these
common variations has also been explored systematically
in some common diseases, but the CNV associations
found are far less than that for SNPs [10, 11]. In the case
of IBD, copy number differences in a complex region
encompassing ß defensin 2 gene cluster [12] as well as a
20 kb deletion upstream of IRGM [13] have been re-
ported as associated with Crohn’s disease (CD), another
subphenotype of IBD which has many (>110) suscepti-
bility loci shared with UC [5].
Rare CNVs (frequency <1 %) that mainly involve larger
genomic segments (>100 kb) and occur in fewer copy
number states (mostly single copy gain/loss) have been
linked extensively to in-born or early-onset neurodeve-
lopmental and intellectual disability disorders with se-
vere and (or) syndromic clinical manifestations [10].
These deleterious CNVs, like other aberrant structural
rearrangements - generally known as genomic disorders
- mostly arise de-novo, are highly penetrant and although
recurrent but individually transmit in the population
through only one or few generations due to the strong
negative selection against them. On the other hand,
evidences exist of pathogenic rare CNVs with more
moderate effect sizes, which contribute individually or
collectively to the susceptibility of common disease phe-
notypes with lower morbidity/mortality like in Autism,
Schizophrenia and Epilepsy [14–16]. Despite this, the
potential contribution of rare CNVs to the risk of other
complex common diseases like UC is still understudied.
To examine whether rare genetic alterations in the form
of CNVs affect susceptibility to UC, we employed an
existing UC data set, which was used in our previous
SNP-GWAS study [17]. The applied platform, Genome-
wide human SNP array 6.0, consists of about two million
(SNP and copy-number) probe sets and enabled detec-
tion of CNVs larger than 15 kb [18]. We investigated
CNVs genome-wide using an approach that detects
enrichment of multiple overlapping rare variants. Rare
deletions and duplications overrepresented in UC cases
were identified in the discovery panel. Subsequent vali-
dations through independent platform as well as further
targeted and in silico replications were used to verify the
CNVs showing the trend of association with UC.
Methods
Study cohorts
We recruited five case control sample sets, one as screen-
ing (discovery) panel for rare CNVs and four others for
follow-up. Here we describe them upon the platform used
for CNV genotyping and origin of the samples;
Array-sample sets
Initial screening cohort consisted of 1121 German UC
patients and 1770 healthy controls, previously used in
our SNP-GWAS experiment using the Affymetrix®
Genome-wide Human SNP array 6.0 (Affy6.0) and has
been described previously [17]. Details about DNA prep-
aration and sample processing are also described in
Additional file 1. Additionally the Affy6.0 data sets of
two independent cohorts, one Norwegian and one from
UK were recruited. The Norwegian study population
consisted of 274 clinically well-characterized UC patients
and an ethnically and sex-matched group of Norwegian
healthy controls (n = 282), also described previously [17].
The UK study population was part of the “Welcome
Trust case-control consortium 2” used for UC GWAS
[19] and contained data sets of 2396 UC cases and 4886
controls after processing and filtrations described in
Additional file 1.
TaqMan sample sets
Included two disease cohorts originated from Germany
and Lithuania which were genotyped for initially selected
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CNVs through real-time PCR automated by TaqMan
CNV assays (see below). The German UC patients con-
sisted of 245 males and 315 females. The German con-
trols consisted of 779 females of age 18 to 81 (average
age: 51) and 637 males of age 27 to 75 (average age: 50),
obtained through the biobank PopGen (http://www.pop
gen.de). The Lithuanian study population consisted of
443 UC patients and a control group of 1157 ethnically,
age and sex-matched healthy blood donors.
Patient recruitment and ethics
Diagnosis of UC was based on the review of the patients’
original medical records including colonoscopies at the
recruiting university hospitals. The currently accepted
pathophysiological characteristics of UC include exclu-
sive inflammation of the colon, continuity of inflamma-
tion, histological evidence for an inflammation limited to
the mucosa, absence of granuloma, intestinal tract archi-
tectural changes including crypt abscesses, leukocyte
aggregates, distortion of crypt architecture and cryptitis,
mucosal edema, and infiltration of neutrophils [20].
These clinical parameters were used to document dis-
ease activity as colitis activity index (CAI) [21]. For UC
patients, Inclusion criteria were CAI ≥ 4 and endoscopic-
ally active disease in the sigmoid colon. Written, in-
formed consent was obtained from all study participants
and study setup and all protocols were approved by the
national and institutional ethical review committees of
the participating centers. A more detailed description of
the involved centers in sample recruitment and ethical
approval is found in Additional file 1.
In silico control sample sets
Comprised altogether 6724 individuals recruited in pre-
vious genotyping studies as; 60 unrelated HapMap CEU
samples genotyped with the Illumina 1 M Dua SNP
array [21], 445 CEU controls genotyped with the Illu-
mina 500 k v3 [22], 283 Caucasian controls genotyped
with the Illumina Human Hap 300 and 231 Caucasian
controls genotyped with the Illumina Human 610-Quad
BeadChip [23], 653 Caucasian controls genotyped with
the Illumina Human Hap 300 and 551 Caucasian con-
trols genotyped with the Illumina Human 610-Quad
BeadChip [24, 25], 3181 European controls genotyped
with the Affymetrix® Human SNP array 6.0 [26].
Additional file 1: Table S2 provides the detailed probe
coverage of these different platforms for the three specific
genomic loci (CNVs) that we evaluated in these samples.
CNV calling of SNP array datasets
Raw image files were converted into CEL-files by Affyme-
trix® genotyping console, which were then processed with
the Affymetrix Power Tools (APT) apt-copynumber-
workflow v 1.67. The values for contrastQC (based on
Affymetrix® GTC 3.0.1 User Manual) and MAPD were
extracted and samples that failed default QC values were
discarded (MAPD> 0.4 and/or contrastQC < 0.4). For the
remaining samples an identity by state (IBS) and principal
component analysis (PCA) was performed as described pre-
viously [17]. The output of apt-copynumber-workflow was
used as the input file for our in-house developed CNV data
mining tool “CNVineta” [27]. A preliminary batch-wise fil-
tering was performed based on the number of called CNVs
per samples. Outliers were defined as samples which had
more CNVs than the 75 % quantile plus 1.5 fold of the
interquantile range. A rigorous manual raw data inspection
for identifying false-negative and -positive CNVs was done
subsequently. For the whole data mining process, the
predicted CNVs with less than five supporting probes per
CNV and mean probe set distance less than one kilobase,
were ignored.
TaqMan® copy number analysis
Real-time PCR for copy number detection through
TaqMan CNV assays was performed as described by Mayo
and colleagues [28]. Copy number status of the samples
was determined with the software CopyCaller v1.0 from
Life Technology (Foster City, CA, USA) for which samples
with confirmed and known deletion or duplication were
used as calibrator samples (Additional file 1: Figures S3-
S5). For technical replication of the CNVs identified
during the initial screening, no calibrator sample was in-
cluded as due to the low frequency of the selected CNVs,
we assumed that the majority of samples have a copy
number state of two. We discarded samples with confi-
dence values < 95 % and/or z-score ≥ 2.65. At least three
of the four technical replicates had to be included for the
calculation of confidence values and z-scores.
Array CGH (aCGH)
Custom CGH 4 × 72 K Array provided by Nimblegen was
used for fine mapping of one deletion and two duplications
of interest in 13 individuals. Bed files of the probe design
based on NCBI’s build hg18 can be downloaded as
Additional file 1. The following regions were covered
by the array: chr13:94757799-94817490, chr7:5667022-
6057428 and chr8:140281592-140630270.
Expression analysis
Endoscopic biopsies from the sigmoid colon of 62 UC
patients, of which two individuals carried the relevant
deletion, were recruited for gene expression analysis as
described previously [21]. TaqMan® pre-designed expres-
sion assays were Hs01075312_m1 for CLDN10 and
Hs00988717_m1 for ABCC4.
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Breakpoint mapping
Based on the genomic resolution provided by custom
aCGH for the deletion, five flanking primers at each end of
the predicted deletion were designed. The subsequent PCR
then only yielded amplicons, if a deletion was present
(without deletion the fragment is longer than 15 kb, no
long range PCR was performed). All possible primer com-
binations were tested and an amplified fragment of about
610 nucleotides was used for Sanger sequencing. (Forward
Primer: 5′-TCCTTCCAGCATATCCCATC; Reverse
Primer: 3′- GAATACTGATAACCACAAACAGACAGA).
The resulted sequence was then used for BLAT query
with the human genome sequence hg18 reference. For the
duplications, breakpoints were derived from the aCGH
mapping experiment.
Results
An overall workflow of this study is outlined in Fig. 1.
Initially a total of 2891 SNP array 6.0 CEL files (1121
German UC patients/1770 matched controls) were sub-
jected to CNV calling, which then left 2466 samples (902
cases/1564 controls) after discarding outliers with re-
spect to raw data quality, per sample call rate, ethnic ori-
gin and relatedness. The primary aim was to identify
rare variants in UC patients, which were absent or were
underrepresented in controls. Therefore, regions of
interest were defined in the primary sample as genomic
segments containing CNVs in at least three cases and in
no controls. This selection criterion was based on the
inspection of the raw data plots where too many false-
positives were among the singleton and doubleton
Fig. 1 Analysis Workflow. Affymetrix 6.0 data sets for the German (discovery) sample as well as WTCCC2 (UK replication) sample were processed
with Affymetrix power tools (APT). Sample cleaning was based on identity by state (IBS) and principal component analysis (PCA) to exclude
non-Caucasian samples as well as relatives. The remaining data sets were converted into the CNVineta format. 151 CNVs overrepresented in
cases were identified after screening for rare CNVs in the German discovery sample, of which 14 deletion and 10 duplications remained after
manual inspection. These 24 CNVs were further evaluated in two independent replication samples, one German and one British (WTCCC2).
Dup7p22.1 and Dup8q24.3 were relevant only in UK (Affy6.0) sample, while Del13q32.1 was replicated only in the German (TaqMan) sample.
Fine mapping for the deletion was done by Sanger sequencing, while custom array-CGH was used for the two duplications. The status of the
3 relevant CNVs was further evaluated in a Norwegian sample (Affy6.0), a Lithuanian sample (TaqMan) and a control sample of various European individuals
from previous published studies. Details of the in silico controls (origins, genotyping platform and probe coverage for the three CNV regions) are found in
Additional file 1: Table S2. M.A.R.V (Mega Analysis of Rare Variants) approach was used for combining data from different panels
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predicted events. Furthermore deletions or duplications
with one carrier among the controls were also included,
when at least five cases contained the corresponding
event. Those CNVs occurred in more than two controls
were excluded. Upon this setting, the discovery sample
yielded 151 CNV regions through screening with our
data-mining tool CNVineta. These were then inspected
manually and CNV regions were discarded when; pre-
dicted event overlapped known common CNVs; had a
complex breakpoint pattern; covered by less than 10
probe sets or spanned large genomic gaps (e.g. if a pre-
dicted CNV contained a gap which was larger than the
part(s) covered by array probes). Twenty-four candidates
(14 deletions and 10 duplications) remained after man-
ual inspection of their Z-scores, Log R ratio and B-allele
frequency traces (Additional file 1: Figure S1). The status
of these 24 CNVs were then evaluated in two independ-
ent cohorts; the WTCCC2 sample (form UK), with CNV
genotypes called from Affy6.0 intensity data, and a Ger-
man cohort (453 UC patients, 1377 controls) genotyped
for the selected CNVs by quantitative PCR through
TaqMan CNV assays. In British cohort (2394 cases, 4886
controls), of the 24 CNVs evaluated, two duplication
events (single copy gains) were the only variants that
showed the same distribution trend as the discovery
panel, i.e. more represented in cases compared to con-
trols; A 119 kb large duplicated region at 7p22.1 carried
by three cases and no control (3/902 cases, 0/1564 con-
trols in discovery panel) and a 134 kb duplication at
8q24.3 with 0.21 % occurrence in cases versus 0.04 % in
controls, two-sided Fisher’s exact P = 0.058 (P = 0.018 in
discovery). (Table 1, Additional file 1: Table S1). These
two duplications however, were not relevant in the
German replication panel, as from the sum of 1830 sam-
ples (cases + controls) genotyped for these two variants
only one individual (UC case) carried the duplication
(Dup8q24.3). Further, of the 24 CNVs followed-up in the
German replication panel, a 15.8 kb deletion (single copy
loss) at 13q32.1 (chr13: 94,781,525-94,797,285), repro-
duced the trend of association with nominal P-value of
0.005 (P = 0.027 in discovery). (Table 1, Additional file 1:
Figure S2). Del13q32.1 was not correlated with UC in
the WTCCC2 sample. For this deletion and the two
aforementioned duplications, we did a validation step, in
which the genotypes of all 13 individuals of the discovery
panel predicted to carry these 3 CNVs (6 with
Del13q32.1, 3 with Dup7p22.1 and 4 with Dup8q24.3)
were confirmed through TaqMan assays (Additional file
1: Figure S3). Furthermore we mapped the physical ex-
tent of these 3 CNVs more precisely and beyond the
resolution of Affy6.0. Figure 2 shows the regional plot of
these 3 CNV events, with their breakpoints resolved
through custom high density a-CGH. The status of these
3 CNVs was additionally assessed in one small
Norwegian sample with affy6.0-based CNV calls as well
as a Lithuanian sample (445 cases, 1140 controls) geno-
typed through corresponding TaqMan CNV assays
(Additional file 1: Figures S4–S6). The combined study-
wide Fisher’s exact test P-value for deletion at 13q32.1
was 1.2 × 10−3 (OR = 2.64), the duplication at 7p22.1 had
a P-value of 2.7 × 10−3 (OR = 8.41) and the duplication
at 8q24.3 had a P-value of 8.7 × 10−4 (OR = 4.62).
Table 1 lists all panel-wise frequencies as well as com-
bined P-values calculated upon “Mega-Analysis of
Rare Variants” approach (M.A.R.V) [29] for combining
data from different panels of this study.
For Del13q32.1, fine mapping through high density a-
CGH followed by Sanger sequencing identified the
sequence motif 5′-GATCAC-3′ at both breakpoints of
the deleted segment. As the deletion is flanked by 16
highly identical Alu repeats, it is very likely that non-
allelic homologous recombination (NAHR) is the under-
lying mechanism of the event [30]. We further analyzed
the expression levels of the two nearby genes of this
deletion, namely ABCC4 and CLDN10 in inflamed intes-
tinal biopsies of two patients harboring the deletion and
60 UC patients without it (Additional file 1: Figure S7).
Intriguingly, the CLDN10 expression was significantly
lower in both deletion-carrier patients in comparison
with the median expression of non-carriers within in-
flamed mucosa.
Discussion
Employing our existing UC-GWAS data set for CNV
calling coupled with our in-house developed CNV data-
mining tool, we performed a genome-wide scan for rare
CNVs associated with UC. After follow-up genotyping in
four independent case control samples we identified
three rare candidate CNVs, one deletion and two dupli-
cations as overrepresented (at a nominal significance) in
UC patients, compared to controls. Del13q32.1, as a
15.8 kb single copy loss at chr13: 94,781,525-94,797,285
showed the trend of association in the discovery panel,
which was reproduced in the so called TaqMan replica-
tion panel originated from Germany. However, correl-
ation of Del13q32.1with the disease phenotype was not
observed in the WTCCC2-UC panel. The two duplica-
tions i.e. Dup7p22.1 (chr7:5,786,323-5,905,210) and
Dup8q24.3 (chr8:140,390,975-140,524,875) were over-
represented in UC patients of the discovery panel (com-
pared to controls) and this trend was replicated in the
WTCCC2 cohort, although no association was seen for
these duplications in two independent replication panels
with German and Lithuanian origins. We further evalu-
ated the status of these three CNVs in an in silico data
set comprising a total of 6727 unrelated control individ-
uals of European ancestry. The scarce occurrence of the
three variants (5 of 4505 for Del13q32.1, 1 of 5788 for
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Table 1 Summary of association statistics
Locus: Deletion 13q32.1 Duplication
7p22.1
Duplication
8q24.3
Breakpoints: chr13:94,781,525-94,
797,285
chr7:5,786,323-5,
905,210
chr8:140,390,975-
140,524,875
Previously
reported:
DGV(Variation_49277) DGV(Variation_53516)
CNV size: 15.8 kb 119 kb 134 kb
Covered or close
genes:
ABCC4, CLDN10 ZNF815, OCM, RNF216, RSPH10B KCNK9
cases controls P-value OR cases controls P-value OR cases controls P-value OR
wt cc wt cc (95 % CI) wt cc wt cc (95 % CI) wt cc wt cc (95 % CI)
Germany (discovery)
Affy6.0
897 5 1563 1 0.027 8.71 899 3 1564 0 0.043 Inf 898 4 1564 0 0.018 Inf
(0.97 - 411) (0.72 - Inf) 0.45 0.00 (1.15-Inf)
Germany (replication)
TaqMan
445 6 1272 2 0.005 8.56 453 0 1279 0 >0.05 452 1 1377 0 >0.05
(1.52-87.2)
WTCCC2 (UK)
Affy6.0
2391 5 4880 6 >0.05 2393 3 4886 0 0.061 2391 5 4884 2 0.058 3.40
(0.66 - 21.9)
Norwegian
Affy6.0
251 1 272 0 0.36 252 0 272 0 >0.05 252 0 272 0 >0.05
Lithuanian
TaqMan
442 2 1131 2 >0.05 438 0 1139 1 >0.05 445 0 1134 0 >0.05
in silico controls
European-ancestry
combined results
– – 4501 5 —— – – 5788 1 ——— – – 6724 3 ———
4426 19 13619 16 1.2 × 10 −3 2.64 4435 6 14928 2 2.7 × 10 −3 8.41 4438 10 15955 5 8.7 × 10 - 4 4.62
0.43 % 0.11 % (1.3–5.2) 0.13 % 0.01 % (1.4–88) 0.22 % 0.03 % (1.5–15)
Bonferroni corrected 3.6 × 10 −3 8.1 × 10 −3 2.6 × 10 −3
MARV 4.3 × 10 −3 6.2 × 10 −3 2.8 × 10 −3
Frequencies are presented panel-wise and combined for the 3 relevant CNVs. P-values were calculated by two-sided Fisher’s exact tests for CNV carriership. Odds ratios (OR) with 95 % confidence intervals (95 % CI;
inf = infinite) are listed when P-values are smaller than 0.05. cc refers to CNV carrier individuals and wt (wildtype) to non-carriers. To account for population structure and low frequencies, the M.A.R.V. analysis method
[29] was applied to the overall study sample
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Dup7p22.1 and 3 of 6727 for Dup8q24.3), observed in
these samples was consistent with their low frequencies
in our discovery and replication panels.
It should be mentioned that CNV discovery plat-
form used here (Affy6.0), although having a high
probe density, has the limited resolution of detecting
CNVs that are larger than ~15 kb [9]. Therefore, pos-
sible smaller CNV events (<15 kb), probably of dis-
ease relevance, have not been examined in our study.
On the other hand in comparison to the small me-
dian size of common CNVs (~3 kb) in the human
genome [8, 10], the three rare CNVs identified here,
are intermediate to large genomic alterations, involv-
ing regions with multiple genes, which can potentially
result in functional (deleterious) consequences leading
to disease pathogenesis.
Dup7p21.1 indeed lies in a very gene rich region,
encompassing either their entire lengths (ZNF815,
OCM) or overlapping (RNF216, RSPH10B) partially.
Dup8q24.3 is a 134 kb large duplication upstream of
the gene KCNK9 (TASK3), which encodes a member
of the subfamily K of the potassium channel proteins.
The ever-increasing knowledge about the involvement
of TASK3 (TWIK-related acid-sensitive potassium)
channels in the pathogenesis of autoimmune inflam-
mation [31, 32] have converted them from “mere
background” channels to key modulators in patho-
physiological conditions.
Del13q32.1 is located 33.7 kb upstream of the gene
ABCC4 (ATP-binding cassette, sub-family C, member 4)
also known as MRP4 (multidrug resistance-associated
protein4), and 78.5 kb upstream of CLDN10 (claudin
10). ABCC4/MRP4 belongs to a large family of trans-
membrane proteins which play an important role in
regulating cAMP-dependent signaling pathways [33] as
well as human dendritic cell migration and thereby
modulating immune response [34]. Mapping of MRP
protein expression among different regions of the hu-
man intestinal tract has showed that MRPs are higher
expressed in the colon compared to the ileum [35].
Interestingly, one member of this protein family i.e.
ABCC1/MRP1 has been previously associated with se-
vere UC but not with CD [36]. The other neighboring
gene CLDN10, coding for a tight junction adhesion pro-
tein is also an intriguing candidate regarding the
molecular pathogenesis of UC. Tight junctions contrib-
ute essentially to the intestinal epithelial integrity. Bar-
rier disruptions are known to be one of the main
hallmarks of both phenotypes (CD and UC) of inflam-
matory bowel disease and various genes involved in epi-
thelial barrier maintenance have been associated with
IBD [37–39]. Moreover, changes in expression and
distribution of Claudin 2, 5 and 8 have been shown to
result in discontinuous tight junctions and barrier dys-
function in active CD [40]. For interrogating the prob-
able effect of the deletion on the expression of the two
nearby genes, we examined two intestinal biopsy
samples of unrelated patients carrying the deletion.
Compared with the CLDN10 expression level of the
deletion-depleted UC patients in inflamed mucosa, the
biopsy specimen from the patient with the deletion
showed very low level of expression. Yet, this differential
expression was not clear for ABCC4. Due to the sparsity
of the deletion variation, no more biopsies from distinct
patients harboring the deletion were available to further
verify the effect of deletion on the expression of these two
genes. However, presence of cis-acting regulatory ele-
ments such as transcription factor binding sites, showed
in ENCODE annotations of the deleted region might be
an explanation of the distinct CLDN10 expression we
observed here.
Overall we find that the rare CNV candidates of
this study, verified by visual inspection of the under-
lying raw data, are true positive CNVs. All three
relevant CNVs could technically be validated by inde-
pendent methods and were followed-up in independ-
ent sample sets. In contrast to common variants,
disease correlation of rare variants is difficult to be
assessed through classical association statistics. Low
frequency of these variants impedes to detect associa-
tions at the genome-wide level significance by modest
or intermediate sample sizes. Power limitations may
even increase when these variants do not have high
penetrance. In this study, the trend of association
with UC was present for each of the three mentioned
copy number variants in the discovery sample as well
as in at least one replication panel, nevertheless
higher statistical power, provided by larger case con-
trol samples are needed to confidently evaluate the
disease risk of these variants.
(See figure on previous page.)
Fig. 2 Regional Plots for Del13q32.1 (a), Dup7p22.1 (b) and Dup8q24.3 (c). For each CNV, SNP6.0 array intensity data (lower panel), custom aCGH
(middle panel) and ENCODE annotations (upper panel) are visualized. The RefSeq genes are shown in SNP array intensity panel with horizontal
orange lines for genes in reverse orientation and purple lines in forward. The red horizontal bar represents the prediction of the deleted segment
while the blue bars show duplications. a The 15.8 kb deletion at chr13: 94,781,525 - 94,797,285 upstream of ABCC4 and CLDN10. b The 119 kb
duplication at chr7:5,786,323-5,905,210 encompasses the entire length of the genes ZNF815 and OCM, and partially overlaps CCZ1 and RNF216.
c The 134 kb large duplication at 8q24.3 (chr8:140,390,975-140,524,875) located upstream of KCNK9. An incidence peak (at 140,450 kb) of
cis-acting regulatory elements is annotated in the genomic region affected by Duplication
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Conclusion
Our multi-step case control analysis introduced rare
structural variants with a potential contribution to the
risk of UC. While further follow-up studies in larger
disease cohorts as well as functional experimental assays
are needed to conclusively verify the disease relevance of
these three loci, we showed that existing GWAS data
sets may still be of use in extending the knowledge of
genetic etiology in common complex diseases.
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